Brought to you by 
Shanghai start-up Laekna gains exclusive license to Novartis prostate cancer compound CFG920
19 May 2022
Executive Summary
Laekna Therapeutics Shanghai Co. Ltd. acquired exclusive global rights from Novartis Pharma AG to develop, manufacture, and commercialize its CFG920 (Laekna renamed LAE001) oral CYP17 inhibitor for prostate cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shanghai start-up Laekna gains exclusive license to Novartis prostate cancer compound CFG920
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice